Report cover image

Orthostatic Hypotension Drugs Market by Product (Droxidopa, Fludrocortisone, Indomethacin), Diagnostics Test type (Blood Tests, ECG, Echocardiogram), End-Use - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 198 Pages
SKU # IRE18448630

Description

Orthostatic Hypotension Drugs Market by Product (Droxidopa, Fludrocortisone, Indomethacin), Diagnostics Test type (Blood Tests, ECG, Echocardiogram), End-Use - Global Forecast 2024-2030


The Orthostatic Hypotension Drugs Market size was estimated at USD 879.78 million in 2023 and expected to reach USD 953.89 million in 2024, at a CAGR 8.51% to reach USD 1,559.07 million by 2030.

Global Orthostatic Hypotension Drugs Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Orthostatic Hypotension Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Orthostatic Hypotension Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Orthostatic Hypotension Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Apotex Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche AG, H. Lundbeck A/S, Koninklijke Philips N.V., Lupin Limited, Merck KGaA, Mylan N.V., Novartis AG, PerkinElmer Inc., Pfizer Inc., Sun Pharmaceutical Industries, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Orthostatic Hypotension Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Droxidopa
Fludrocortisone
Indomethacin
Midodrine Hydrochloride
NSAIDs
Pyridostigmine
Diagnostics Test type
Blood Tests
ECG
Echocardiogram
Stress Test
End-Use
Ambulatory Surgical Centers
Clinics
Diagnostic Centers
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Orthostatic Hypotension Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Orthostatic Hypotension Drugs Market?
3. What are the technology trends and regulatory frameworks in the Orthostatic Hypotension Drugs Market?
4. What is the market share of the leading vendors in the Orthostatic Hypotension Drugs Market?
5. Which modes and strategic moves are suitable for entering the Orthostatic Hypotension Drugs Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

198 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Orthostatic Hypotension Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growth in the prevalence of chronic diseases associated with high risk of orthostatic hypotension
5.1.1.2. High pharmaceutical expenditure and increased awareness of orthostatic hypotension
5.1.1.3. Presence of several major players and improvement in healthcare facilities
5.1.2. Restraints
5.1.2.1. Hypotensive medications frequently overlap with other risk factors increasing further complications
5.1.3. Opportunities
5.1.3.1. Integration of advanced technologies in healthcare
5.1.3.2. Large investments and collaborations for development of new drugs
5.1.4. Challenges
5.1.4.1. Difficult to improve the symptoms of orthostatic hypotension without inducing some degree of supine hypertension
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Orthostatic Hypotension Drugs Market, by Product
6.1. Introduction
6.2. Droxidopa
6.3. Fludrocortisone
6.4. Indomethacin
6.5. Midodrine Hydrochloride
6.6. NSAIDs
6.7. Pyridostigmine
7. Orthostatic Hypotension Drugs Market, by Diagnostics Test type
7.1. Introduction
7.2. Blood Tests
7.3. ECG
7.4. Echocardiogram
7.5. Stress Test
8. Orthostatic Hypotension Drugs Market, by End-Use
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Diagnostic Centers
8.5. Hospitals
9. Americas Orthostatic Hypotension Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Orthostatic Hypotension Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Orthostatic Hypotension Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. Apotex Inc.
13.1.3. Boehringer Ingelheim GmbH
13.1.4. Eli Lilly and Company
13.1.5. F. Hoffmann-La Roche AG
13.1.6. H. Lundbeck A/S
13.1.7. Koninklijke Philips N.V.
13.1.8. Lupin Limited
13.1.9. Merck KGaA
13.1.10. Mylan N.V.
13.1.11. Novartis AG
13.1.12. PerkinElmer Inc.
13.1.13. Pfizer Inc.
13.1.14. Sun Pharmaceutical Industries, Inc.
13.1.15. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. ORTHOSTATIC HYPOTENSION DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ORTHOSTATIC HYPOTENSION DRUGS MARKET DYNAMICS
FIGURE 7. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2023 VS 2030 (%)
FIGURE 10. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY DIAGNOSTICS TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ORTHOSTATIC HYPOTENSION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ORTHOSTATIC HYPOTENSION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ORTHOSTATIC HYPOTENSION DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us